Company Information

Halozyme Therapeutics Inc.

Member Type

Associate

Organization Type

Manufacturer

Description

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the diabetes, oncology, dermatology, and drug delivery markets. The company's product portfolio is primarily based on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's ENHANZE™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Baxter, Roche, ViroPharma and Intrexon to apply ENHANZE™ technology to biological therapeutics, including immunoglobulin, Herceptin®, MabThera®, Cinryze® and alpha 1-antitrypsin. Halozyme’s Ultrafast Insulin program combines its rHuPH20 enzyme with mealtime insulins, which may produce more rapid absorption, faster action, and improved glycemic control. The product candidates in Halozyme's pipeline target significant areas of unmet medical need.

Contact Information

12390 El Camino Real

San Diego, CA 92130

http://www.halozyme.com

(858)794-8889

Services Offered

Branded

Specialty

Staff

• Berry, Marie

  Senior Director, Supply Chain Operations, Halozyme Therapeutics Inc.

• Callaway, Donna

  Executive Assistant, Halozyme Therapeutics Inc.

• Eaton, Patrick

  Senior Manager, Manufacturing, Halozyme Therapeutics Inc.

• Frost, Gregory

  President, Halozyme Therapeutics Inc.

• McAdams, Kevin

  Vice President, Managed Markets, Halozyme Therapeutics Inc.

• Nelson, Robert

  Manager, Logistics, Halozyme Therapeutics Inc.

• Torley, Helen

  President, Chief Executive Officer and member of the Board of Directors, Halozyme Therapeutics Inc.